Predictive Oncology Inc. Announces Proposed Public Offering of Common Stock
October 01 2019 - 5:45PM
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the
Company”) today announced a proposed public offering of its common
stock. The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Dawson James Securities, Inc. and Paulson Investment Company,
LLC are acting as exclusive placement agents for the offering.
Predictive intends to use the net proceeds from the offering, if
completed, for working capital and general corporate purposes.
Predictive may also use a portion of the net proceeds to repay
indebtedness.
The offering is being made by Predictive pursuant to a shelf
registration statement previously filed with the Securities and
Exchange Commission (the “SEC”) and declared effective on October
4, 2016. The offering of the securities will be made only by means
of a prospectus supplement and accompanying prospectus. A
preliminary prospectus supplement and accompanying prospectus
related to the offering has been filed with the SEC and is
available on the SEC’s website at http://www.sec.gov. Copies of the
preliminary prospectus supplement and accompanying prospectus may
also be obtained by contacting Dawson James Securities, Inc.,
Attention: Prospectus Department, 1 North Federal Highway, 5th
Floor, Boca Raton, FL 33432, or by telephone toll free at (866)
928-0928, or by email at mmaclaren@dawsonjames.com, or Paulson
Investment Company, LLC, 40 Wall Street, 23rd Floor, New York, NY
10005 Attention: Marta Wypych at mwypych@paulsoninvestment.com or
by telephone at (646) 630-8891.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates in two business
areas: first, applying artificial intelligence to personalized
medicine and drug discovery to provide personalized medicine
solutions for patients and clinicians as well as clients in the
pharmaceutical, diagnostic, and biotech industries, and second,
production of the FDA-approved STREAMWAY® System for automated,
direct-to-drain medical fluid disposal.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements related to Predictive’s public offering of
common stock and warrants and the completion of the offering that
involve risks and uncertainties. These forward-looking statements
are based upon Predictive’s current expectations. Actual results
and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of risks
and uncertainties, which include, without limitation, risks and
uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed offering and other risks detailed in Predictive’s filings
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Predictive undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
ContactBob Myers, Predictive Oncology Inc.651-389-4800
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Sep 2023 to Sep 2024